SCHEMBL4602701

SCHEMBL4602701

COCCCOc1cc(C)cc(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
AHR P35869 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPC1 O15118 2/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
ACHE P22303 1/20 0.38
RECQL P46063 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
F2 P00734 1/20 0.37
KCNA3 P22001 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13433987 0.94 TP53 (0.44) ALDH1A1TP53ALOX15MEN1KMT2A
SCHEMBL4604583 0.90 ALDH1A1 (0.46) ALDH1A1TP53ALOX15AHRMEN1
SCHEMBL16951162 0.84 AHR (0.57) ALDH1A1TP53ALOX15AHR
SCHEMBL19399855 0.83 MEN1 (0.45) ALDH1A1TP53ALOX15MEN1KMT2A
SCHEMBL13095985 0.82 TP53 (0.51) ALDH1A1TP53ALOX15AHRNPC1
SCHEMBL10921819 0.82 ALDH1A1 (0.42) ALDH1A1TP53ALOX15AHRMEN1
SCHEMBL4602697 0.82 ALDH1A1 (0.42) ALDH1A1AHRMEN1KMT2ACYP1A2
SCHEMBL425611 0.82 ALDH1A1 (0.42) ALDH1A1AHRMEN1KMT2ACYP1A2
SCHEMBL13433978 0.82 KDM4E (0.38) ALDH1A1TP53ALOX15MEN1KMT2A
SCHEMBL13095984 0.82 AHR (0.46) ALDH1A1TP53ALOX15AHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242662-A1 Organic Compounds NIHONYANAGI ATSUKO 2008-10-02 US claimed
EP-1915366-A2 PIPERAZINE DERIVATIVE RENIN INHIBITORS Novartis AG (CH) 2008-04-30 EP claimed
WO-2006128659-A2 PIPERAZINE DERIVATIVE RENIN INHIBITORS. NOVARTIS AG (CH) 2006-12-07 WO claimed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed
US-20080242662-A1 Organic Compounds NIHONYANAGI ATSUKO 2008-10-02 US disclosed
EP-1915366-A2 PIPERAZINE DERIVATIVE RENIN INHIBITORS Novartis AG (CH) 2008-04-30 EP disclosed
WO-2006128659-A2 PIPERAZINE DERIVATIVE RENIN INHIBITORS. NOVARTIS AG (CH) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242662-A1 Organic Compounds REN, ACE, ECE1 ALDH1A1 13/4885TP53 3502/4885ALOX15 466/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 ALDH1A1 348/4885TP53 4754/4885ALOX15 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.